Fertility preservation not linked to higher breast cancer relapse, mortality risk
Women who undergo hormonal or nonhormonal fertility preservation procedures following breast cancer diagnosis are not at increased risk for relapse or breast cancer-specific mortality, Swedish study findings indicate.
People with type 2 diabetes and CKD missing out on renoprotective drugs
People with type 2 diabetes and chronic kidney disease are substantially less likely to initiate SGLT2 inhibitors than those with normal kidney function, despite their proven renoprotective benefits, research shows.
CV risk reduction should be ‘an integral part’ of autoimmune disease management
A large study published in The Lancet has found that people with autoimmune diseases have an approximately 1.4–3.6-fold increased risk for developing cardiovascular disease relative to the general population.
‘Substantial improvement’ in COVID-19 outcomes over time for RMD patients
The proportion of people with rheumatic and musculoskeletal diseases experiencing severe COVID-19 has declined since the beginning of the pandemic, particularly during the recent Omicron wave, US researchers report.
Genetic study emphasizes ‘central role’ of complement pathway in SLE, pSS
A combination of partial deficiencies affecting the C2 and C4A classical complement pathway genes may represent a risk factor for the development of systemic lupus erythematosus or primary Sjögren’s syndrome, shows research from Lars Rönnblom and team.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
ARROW update demonstrates first-line pralsetinib benefit for advanced RET fusion-positive NSCLC
Updated findings from the ARROW trial show that pralsetinib has “robust efficacy” for the first-line treatment of locally advanced or metastatic, RET fusion-positive, non-small-cell lung cancer, the investigators say.
Common diabetic peripheral neuropathic pain treatments equivalent in OPTION-DM
Combination therapy with three commonly used medications has achieved similar levels of pain relief for people with diabetic peripheral neuropathic pain in the randomized OPTION-DM trial.
More efforts needed to improve gender equity in academic rheumatology
Findings from two studies highlight the need for interventions to improve gender equity in academic rheumatology career advancement and on journal editorial boards.
Large proportion of global cancer deaths, DALYs attributable to modifiable risk factors
Modifiable risk factors accounted for almost half of the global cancer mortality and disability-adjusted life–years in 2019, shows an analysis of the Global Burden of Diseases, Injuries, and Risk Factors Study.
Pioglitazone may modulate CVD risk in patients with SLE
Pioglitazone, a peroxisome proliferator activated receptor-γ agonist, is associated with improvements in vascular stiffness and various cardiometabolic parameters in patients with systemic lupus erythematosus, show study findings.